8-K current report · filed Nov 9, 2026

Quanterix Corp (QTRX) 8-K Current Report: November 9, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2QTRX overview

Short answer

Quanterix Corp (QTRX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 fiscal 2026 results announced for quarter ended September 30, 2026.

Quanterix Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 fiscal 2026 results announced for quarter ended September 30, 2026
  • Earnings Release furnished as Exhibit 99.1, containing the detailed financial results

Item 7.01 · Regulation FD Disclosure

  • Quanterix furnished investor presentation slides for its November 9, 2026 earnings call
  • Exhibit 99.2 likely contains earnings-period metrics, guidance, and management commentary relevant to valuation
  • Investors should review the slides for updates beyond the filing’s brief disclosure

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $35.0M, up 6.3% sequentially but down from $40.2M year over year, signaling early stabilization amid market softness
  • GAAP gross margin 38.6%, while adjusted gross margin improved to 47.4% from 45.9% year over year
  • Net loss narrowed 35.6% to $21.6M, but adjusted EBITDA loss widened 2.4% to $12.2M
  • Cash, marketable securities and restricted cash totaled $84.1M, with operating cash burn of $39.4M through nine months
  • 2026 revenue outlook narrowed to $142M-$146M, adjusted gross margin remains 48%-50%, and year-end cash expected near $70M with no debt

Item EX-99.2 · Exhibit EX-99.2

  • Q3 revenue $35.0M, down 13% YoY but up 6.3% QoQ, indicating early stabilization after prolonged declines
  • Full-year 2026 revenue guidance narrowed to $142M-$146M, maintaining adjusted gross margin guidance of 48%-50%
  • Q3 adjusted EBITDA loss $12.2M, versus $11.9M prior year, showing profitability remains unresolved despite gross-margin improvement
  • Cash balance $81M at quarter-end, with year-end cash now expected at $70M, highlighting continued cash-burn risk
  • Diagnostics catalysts include $897 CMS pricing for LucentAD Complete and planned 2027 FDA submission for the HD-X IVD instrument

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Quanterix Corp 8-K filings

Get the next QTRX 8-K as it lands

Follow QTRX for push alerts, or ask the research agent what this filing means.